| scholarly article | Q13442814 |
| P2093 | author name string | Hoelzer D | |
| Lechner K | |||
| O'Brien C | |||
| Ganser A | |||
| Noens L | |||
| Barge A | |||
| Papa G | |||
| Sanz MA | |||
| Heil G | |||
| Szer J | |||
| Matcham J | |||
| Liu Yin JA | |||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| acute myeloid leukemia | Q264118 | ||
| placebo | Q269829 | ||
| P1104 | number of pages | 9 | |
| P304 | page(s) | 4710-4718 | |
| P577 | publication date | 1997-12-01 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group | |
| P478 | volume | 90 |
| Q40458935 | A multicenter randomized, double-blind, placebo-controlled late-phase II/III study of recombinant human interleukin 11 in acute myelogenous leukemia. |
| Q33350688 | A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial |
| Q47938059 | A systematic literature review of the efficacy, effectiveness, and safety of filgrastim |
| Q34808062 | Acute myeloid leukaemia: optimising treatment in elderly patients |
| Q37204380 | Chemotherapy-induced neutropenia among pediatric cancer patients in Egypt: Risks and consequences |
| Q37323006 | Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: Practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation |
| Q36806921 | Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia |
| Q24202698 | Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia |
| Q35024453 | Colony-stimulating factors for the management of neutropenia in cancer patients |
| Q33821268 | Colony-stimulating factors in the treatment of older patients with acute myelogenous leukaemia |
| Q36639295 | Colony-stimulating factors: clinical evidence for treatment and prophylaxis of chemotherapy-induced febrile neutropenia |
| Q40197450 | Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia |
| Q35128648 | Cost analyses of adjunct colony stimulating factors for older patients with acute myeloid leukaemia : can they improve clinical decision making? |
| Q30711100 | Economic analysis of filgrastim use for patients with acute myeloid leukaemia in the UK: a comparison of collection methods of resource use data |
| Q36297673 | Effects of granulocyte-colony stimulating factor and the expression of its receptor on various malignant cells |
| Q36527110 | Exogenous endothelial cells as accelerators of hematopoietic reconstitution |
| Q35913455 | Filamentous influenza A virus infection predisposes mice to fatal septicemia following superinfection with Streptococcus pneumoniae serotype 3 |
| Q35024468 | Filgrastim in patients with neutropenia: potential effects on quality of life |
| Q92385917 | Filgrastim prophylaxis in elderly cancer patients in the real-life setting: a French multicenter observational study, the TULIP study |
| Q37354296 | Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium? |
| Q34436603 | Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia |
| Q33336925 | Haemopoietic growth factors in paediatric oncology: a review of the literature |
| Q86594429 | Immunomodulation Therapy for Invasive Aspergillosis: Discussion on Myeloid Growth Factors, Recombinant Cytokines, and Antifungal Drug Immune Modulation |
| Q44799963 | Impact of pegylated filgrastim in comparison to filgrastim for patients with acute myeloid leukaemia (AML) on high-dose cytarabine (HIDAC) consolidation chemotherapy |
| Q39000902 | Impact of recommended weight-based dosing of granulocyte-colony stimulating factors in acute leukemia and stem cell transplant patients |
| Q44003315 | In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia |
| Q40376756 | Infections in acute myeloid leukemia: an analysis of 382 febrile episodes |
| Q40138696 | Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years. |
| Q26768126 | Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients |
| Q40053864 | Management of infection during chemotherapy for acute leukemia in Japan: a nationwide questionnaire-based survey by the Japan Adult Leukemia Study Group. |
| Q50584736 | Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events. |
| Q36597647 | Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs |
| Q34774180 | Older adults with acute myeloid leukemia |
| Q45104478 | Peripheral blood stem cell collection after intermediate-dose cytarabine in adult patients with acute myeloblastic leukemia undergoing autologous blood stem cell transplantation in first complete remission |
| Q24632145 | Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients |
| Q36058475 | Prevention of pegfilgrastim-induced bone pain: a phase III double-blind placebo-controlled randomized clinical trial of the university of rochester cancer center clinical community oncology program research base |
| Q24187043 | Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy |
| Q64075116 | Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML |
| Q35048344 | Randomized trial of 2 dosages of prophylactic granulocyte-colony-stimulating factor after induction chemotherapy in pediatric acute myeloid leukemia. |
| Q37322860 | The Relationship Between Risk Factors and Survival in Adult Acute Lymphoblastic Leukemia |
| Q33874174 | The number of CD34+CD38+CD117+HLA-DR+CD13+CD33+ cells indicates post-chemotherapy hematopoietic recovery in patients with acute myeloid leukemia |
| Q35024465 | The role of myelopoietic growth factors in managing cancer in the elderly |
| Q35291847 | Treatment concepts for elderly patients with acute myeloid leukemia. |
| Q34357504 | Treatment options in Invasive Aspergillosis |
| Q36393320 | Treatment with G-CSF reduces acute myeloid leukemia blast viability in the presence of bone marrow stroma |
| Q87633142 | Use of G-CSF to hasten neutrophil recovery after auto-SCT for AML is not associated with increased relapse incidence: a report from the Acute Leukemia Working Party of the EBMT |
| Q24670020 | Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study |
| Q38913554 | What Is the Optimal Induction Therapy for Younger Fit Patients With AML? |
Search more.